Gilead Sciences Inc
GIS
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
17,000
Stocks News & Analysis
stocks
Our view after CBA shares plunge
Steady profit, but rising risks and rich valuation give pause.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,853.50 | 12.90 | -0.15% |
| CAC 40 | 8,007.97 | 28.05 | 0.35% |
| DAX 40 | 24,136.81 | 181.88 | 0.76% |
| Dow JONES (US) | 49,693.20 | 67.36 | -0.14% |
| FTSE 100 | 10,325.35 | 60.03 | 0.58% |
| HKSE | 26,488.36 | 99.92 | 0.38% |
| NASDAQ | 26,402.34 | 314.14 | 1.20% |
| Nikkei 225 | 63,354.51 | 82.40 | 0.13% |
| NZX 50 Index | 13,005.49 | 57.57 | -0.44% |
| S&P 500 | 7,444.25 | 43.29 | 0.58% |
| S&P/ASX 200 | 8,609.80 | 4.90 | -0.06% |
| SSE Composite Index | 4,199.19 | 43.38 | -1.02% |